Reported 7 months ago
AstraZeneca's CFO, Aradhana Sarin, expressed confidence in the company's oncology portfolio growth, highlighting successful cancer drug data and upcoming product launches. The company aims to reach $80 billion in sales by 2030, focusing on expanding their revenue streams. Sarin emphasized the depth and breadth of the product portfolio, stating that achieving the revenue goal will not rely on one or two blockbusters. With recent stock surges and upcoming data releases, AstraZeneca is poised for further advancements in oncology.
Source: YAHOO